Early treatment with sotrovimab monoclonal antibody in kidney transplant recipients with Omicron infection

Affiliations

¹ Department of Nephrology and Kidney Transplantation, Necker-Enfants Malades Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France; Université de Paris, Paris, France. Electronic address: Nathalie.chavarot@aphp.fr.
² Université de Paris, Paris, France; Department of infectious Diseases and Tropical Medicine, Necker-Enfants Malades Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France.
³ Department of Nephrology and Kidney Transplantation, Necker-Enfants Malades Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France; Université de Paris, Paris, France.
⁴ Infectious Disease Department, Hotel Dieu Hospital, Assistance Publique Hôpitaux de Paris (APHP), Paris Centre Hôtel-Dieu, Paris, France.
⁵ Université de Paris, Paris, France; Virology Laboratory, Necker Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France.
⁶ COVID-19 Screening Center, Emergency Department, Hôtel Dieu Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France.
⁷ Department of Nephrology and Kidney Transplantation, Necker-Enfants Malades Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France.
⁸ Adult Intensive Care Unit, Department of Anaesthesiology, Necker-Enfants Malades Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France.

Nathalie Chavarot et al. Kidney Int. 2022 Jun.

. 2022 Jun;101(6):1290-1293.

doi: 10.1016/j.kint.2022.04.003. Epub 2022 Apr 12.

¹ Department of Nephrology and Kidney Transplantation, Necker-Enfants Malades Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France; Université de Paris, Paris, France. Electronic address: Nathalie.chavarot@aphp.fr.
² Université de Paris, Paris, France; Department of infectious Diseases and Tropical Medicine, Necker-Enfants Malades Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France.
³ Department of Nephrology and Kidney Transplantation, Necker-Enfants Malades Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France; Université de Paris, Paris, France.
⁴ Infectious Disease Department, Hotel Dieu Hospital, Assistance Publique Hôpitaux de Paris (APHP), Paris Centre Hôtel-Dieu, Paris, France.
⁵ Université de Paris, Paris, France; Virology Laboratory, Necker Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France.
⁶ COVID-19 Screening Center, Emergency Department, Hôtel Dieu Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France.
⁷ Department of Nephrology and Kidney Transplantation, Necker-Enfants Malades Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France.
⁸ Adult Intensive Care Unit, Department of Anaesthesiology, Necker-Enfants Malades Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France.

No abstract available

Figures

1. Maslo C., Friedland R., Toubkin M., et al. Characteristics and outcomes of hospitalized patients in South Africa during the COVID-19 Omicron wave compared with previous waves. JAMA. 2022;327:583–584. - PMC - PubMed
1. Ulloa A.C., Buchan S.A., Daneman N., Brown K.A. Estimates of SARS-CoV-2 Omicron variant severity in Ontario, Canada. JAMA. 2022;327:1286–1288. - PMC - PubMed
1. Iuliano A.D., Brunkard J.M., Boehmer T.K., et al. Trends in disease severity and health care utilization during the early Omicron variant period compared with previous SARS-CoV-2 high transmission periods—United States, December 2020-January 2022. MMWR Morb Mortal Wkly Rep. 2022;71:146–152. - PMC - PubMed
1. Gupta A., Gonzalez-Rojas Y., Juarez E., et al. Early treatment for Covid-19 with SARS-CoV-2 neutralizing antibody sotrovimab. N Engl J Med. 2021;385:1941–1950. - PubMed
1. Hoffmann M., Krüger N., Schulz S., et al. The Omicron variant is highly resistant against antibody-mediated neutralization: implications for control of the COVID-19 pandemic. Cell. 2022;185:447–456.e11. - PMC - PubMed